# Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

> **NCT04445454** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Liege** · enrollment: 20 (estimated)

## Conditions studied

- Coronavirus Infection

## Interventions

- **BIOLOGICAL:** Mesenchymal stromal cells

## Key facts

- **NCT ID:** NCT04445454
- **Lead sponsor:** University of Liege
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-12
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445454, "Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04445454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*